NCT03914443View on ClinicalTrials.gov

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Locally Advanced Esophageal Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Nivolumab

240 mg or 360 mg

DRUG

5-FU

750 or 800 mg\^2

DRUG

CDDP

70 or 80 mg/m\^2

DRUG

DTX

70 mg/m\^2

Trial Locations (1)

Unknown

National Cancer Center Hospital, Tokyo

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

collaborator

Fiverings Co., Ltd.

OTHER

lead

National Cancer Center, Japan

OTHER_GOV